Nirali A. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nirali A. Shah has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Alexander B. Karol
Icahn School of Medicine at Mount Sinai, New York, NY
1 shared publicationAmanda Leiter
Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
1 shared publicationAnne S. Linker
Division of Hospital Medicine, Mount Sinai Hospital, New York, NY
1 shared publication- Carol J. Levy
Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication Danielle Brooks
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY
1 shared publication- Danielle Brooks
Division of Endocrinology, Long Island Jewish Medical Center, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY 11040, USA
1 shared publication
Latest Publications
- Open Access
- 12 September 2024
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 11 (1) , 10-13
Finding the Culprit: Cushing Syndrome Secondary to Lung Carcinoid Tumor
- 12 September 2024
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 11 (1) , 10-13
Open AccessFinding the Culprit: Cushing Syndrome Secondary to Lung Carcinoid Tumor
- 2 March 2023
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 41 (3) , 378-385
A Novel Algorithm for the Management of Inpatient COVID-19 Glucocorticoid-Induced Hyperglycemia
Hyperglycemia in hospitalized patients with coronavirus disease 2019 (COVID-19) is linked to increased morbidity and mortality. This article reports on a novel insulin titration protocol for the management of glucocorticoid-induced hyperglycemia in hospitalized patients with COVID-19. Sixty-five patients with COVID-19 and glucocorticoid-induced hyperglycemia admitted after the protocol implementation were matched 1:1 to patients admitted before the treatment protocol rollout for analysis. In a large, diverse health system, the protocol achieved reductions in hypoglycemic events without increasing hyperglycemia or insulin use.
- 2 March 2023
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 41 (3) , 378-385
A Novel Algorithm for the Management of Inpatient COVID-19 Glucocorticoid-Induced Hyperglycemia
Hyperglycemia in hospitalized patients with coronavirus disease 2019 (COVID-19) is linked to increased morbidity and mortality. This article reports on a novel insulin titration protocol for the management of glucocorticoid-induced hyperglycemia in hospitalized patients with COVID-19. Sixty-five patients with COVID-19 and glucocorticoid-induced hyperglycemia admitted after the protocol implementation were matched 1:1 to patients admitted before the treatment protocol rollout for analysis. In a large, diverse health system, the protocol achieved reductions in hypoglycemic events without increasing hyperglycemia or insulin use.
- 1 January 2023
- Published by Springer Nature
- p. 235-252
Inpatient Management of Diabetes During Pregnancy
- 1 January 2023
- Published by Springer Nature
- p. 235-252
Inpatient Management of Diabetes During Pregnancy
- Open Access
- 25 October 2021
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 8 (2) , 78-81
Cushing Disease Treated Successfully With Metyrapone During Pregnancy
- 25 October 2021
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 8 (2) , 78-81
Open AccessCushing Disease Treated Successfully With Metyrapone During Pregnancy
- Open Access
- 13 March 2021
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 7 (5) , 307-309
Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies
- 13 March 2021
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 7 (5) , 307-309
Open AccessMycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies